CA3167139A1 - Peptide compounds and methods of treating diseases using same - Google Patents
Peptide compounds and methods of treating diseases using sameInfo
- Publication number
- CA3167139A1 CA3167139A1 CA3167139A CA3167139A CA3167139A1 CA 3167139 A1 CA3167139 A1 CA 3167139A1 CA 3167139 A CA3167139 A CA 3167139A CA 3167139 A CA3167139 A CA 3167139A CA 3167139 A1 CA3167139 A1 CA 3167139A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- group
- isolated peptide
- seq
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL272074A IL272074B2 (en) | 2020-01-15 | 2020-01-15 | Peptide compounds and methods of treating diseases using same |
| IL272074 | 2020-01-15 | ||
| PCT/IL2021/050044 WO2021144798A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3167139A1 true CA3167139A1 (en) | 2021-07-22 |
Family
ID=76863930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3167139A Pending CA3167139A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230049549A1 (enExample) |
| EP (1) | EP4090347A1 (enExample) |
| JP (1) | JP7809060B2 (enExample) |
| KR (1) | KR20220145826A (enExample) |
| CN (6) | CN119708144A (enExample) |
| AU (1) | AU2021207415A1 (enExample) |
| BR (1) | BR112022013978A2 (enExample) |
| CA (1) | CA3167139A1 (enExample) |
| CO (1) | CO2022011101A2 (enExample) |
| IL (1) | IL272074B2 (enExample) |
| MX (1) | MX2022008746A (enExample) |
| WO (1) | WO2021144798A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| WO2003037172A2 (en) * | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| US8648045B2 (en) * | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| US20130096070A1 (en) * | 2009-04-07 | 2013-04-18 | University Of Kansas | Peptide targeting of inner ear cells |
| CA2836503C (en) * | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| IL280101B2 (en) * | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
-
2020
- 2020-01-15 IL IL272074A patent/IL272074B2/en unknown
-
2021
- 2021-01-14 US US17/792,787 patent/US20230049549A1/en active Pending
- 2021-01-14 EP EP21704023.7A patent/EP4090347A1/en active Pending
- 2021-01-14 CN CN202411888874.5A patent/CN119708144A/zh active Pending
- 2021-01-14 KR KR1020227028077A patent/KR20220145826A/ko active Pending
- 2021-01-14 JP JP2022542986A patent/JP7809060B2/ja active Active
- 2021-01-14 CN CN202411888865.6A patent/CN119708140A/zh active Pending
- 2021-01-14 CN CN202411888870.7A patent/CN119708142A/zh active Pending
- 2021-01-14 CN CN202411888869.4A patent/CN119708141A/zh active Pending
- 2021-01-14 CA CA3167139A patent/CA3167139A1/en active Pending
- 2021-01-14 CN CN202411888873.0A patent/CN119708143A/zh active Pending
- 2021-01-14 CN CN202180017719.4A patent/CN115942948B/zh active Active
- 2021-01-14 AU AU2021207415A patent/AU2021207415A1/en active Pending
- 2021-01-14 MX MX2022008746A patent/MX2022008746A/es unknown
- 2021-01-14 BR BR112022013978A patent/BR112022013978A2/pt unknown
- 2021-01-14 WO PCT/IL2021/050044 patent/WO2021144798A1/en not_active Ceased
-
2022
- 2022-08-04 CO CONC2022/0011101A patent/CO2022011101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022008746A (es) | 2022-10-13 |
| WO2021144798A1 (en) | 2021-07-22 |
| CN119708141A (zh) | 2025-03-28 |
| JP7809060B2 (ja) | 2026-01-30 |
| CN115942948A (zh) | 2023-04-07 |
| EP4090347A1 (en) | 2022-11-23 |
| US20230049549A1 (en) | 2023-02-16 |
| CN119708142A (zh) | 2025-03-28 |
| CO2022011101A2 (es) | 2022-11-08 |
| AU2021207415A1 (en) | 2022-09-08 |
| CN119708144A (zh) | 2025-03-28 |
| JP2023510019A (ja) | 2023-03-10 |
| IL272074B2 (en) | 2024-12-01 |
| CN119708143A (zh) | 2025-03-28 |
| IL272074A (en) | 2021-07-29 |
| CN115942948B (zh) | 2025-01-14 |
| BR112022013978A2 (pt) | 2022-10-11 |
| CN119708140A (zh) | 2025-03-28 |
| KR20220145826A (ko) | 2022-10-31 |
| IL272074B1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10040836B2 (en) | Peptides for the treatment of neurodegenerative diseases | |
| AU2024278477A1 (en) | Peptide compounds and therapeutic uses of same | |
| EP2688582B1 (en) | Neuroprotective peptides | |
| CA2773935C (en) | Peptides for the treatment of oxidative stress related disorders | |
| RU2762089C2 (ru) | ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53 | |
| AU2015291151B2 (en) | Isolated polypeptides of CD44 and uses thereof | |
| CA3167139A1 (en) | Peptide compounds and methods of treating diseases using same | |
| RU2843553C2 (ru) | Пептидные соединения и их терапевтическое применение | |
| EA044784B1 (ru) | Пептидные соединения и способы лечения заболеваний с их использованием | |
| EA051325B1 (ru) | Пептидные соединения и их терапевтическое применение | |
| EA046208B1 (ru) | Пептидные соединения и их терапевтическое применение | |
| US20220251159A1 (en) | Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53 | |
| US20230127559A1 (en) | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241107 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241107 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20241219 Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |